Barclays lowered the firm’s price target on Amdocs (DOX) to $111 from $113 and keeps an Overweight rating on the shares following the CEO roadshow. The company is phasing out low-margin non-core businesses in a move that management indicated will boost recurring revenue and bring fiscal 2025 operating margin north of 21% while delivering double-digit shareholder return, the analyst tells investors in a research note.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.